Expanded Access to Telisotuzumab Vedotin
Sponsor: AbbVie
ClinicalTrials ID:NCT04830202
This expanded access program provides Telisotuzumab vedotin via intravenous infusion to eligible participants who cannot join a clinical trial. A medical doctor must assess the risk-benefit ratio based on the patient's medical history and program criteria. Availability is subject to territory eligibility and local regulatory approval.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Telisotuzumab vedotin prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
Eligibility Criteria
Inclusion Criteria
- The participant must not be eligible for a telisotuzumab vedotin clinical trial.
Get This Program In Your Inbox
Receive detailed information about this treatment opportunity to review with your healthcare provider.